These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20939013)

  • 1. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
    Schultz L; Albadine R; Hicks J; Jadallah S; DeMarzo AM; Chen YB; Nielsen ME; Gonzalgo ML; Sidransky D; Schoenberg M; Netto GJ
    Cancer; 2010 Dec; 116(23):5517-26. PubMed ID: 20939013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.
    Gonzalez-Roibon ND; Chaux A; Al-Hussain T; Osunkoya AO; Bezerra SM; Hicks J; Epstein JI; Netto GJ
    Hum Pathol; 2013 Apr; 44(4):612-22. PubMed ID: 23084634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study.
    Park SJ; Lee TJ; Chang IH
    Korean J Urol; 2011 Jul; 52(7):466-73. PubMed ID: 21860767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
    Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
    Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
    Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
    Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
    Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
    Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
    Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
    Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
    Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
    Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.
    Elwy AE; Elsaba TM; Abd Elzaher AR; Nassar MI
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3735-3746. PubMed ID: 31870116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.